- Home
- JHS vs TCRX Comparison
JHS vs TCRX Comparison
Compare JHS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHS
- TCRX
- Stock Information
- Founded
- JHS 1973
- TCRX 2018
- Country
- JHS United States
- TCRX United States
- Employees
- JHS N/A
- TCRX N/A
- Industry
- JHS Finance Companies
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- JHS Finance
- TCRX Health Care
- Exchange
- JHS Nasdaq
- TCRX Nasdaq
- Market Cap
- JHS 131.4M
- TCRX 123.7M
- IPO Year
- JHS N/A
- TCRX 2021
- Fundamental
- Price
- JHS $11.94
- TCRX $2.12
- Analyst Decision
- JHS
- TCRX Strong Buy
- Analyst Count
- JHS 0
- TCRX 5
- Target Price
- JHS N/A
- TCRX $9.40
- AVG Volume (30 Days)
- JHS 32.8K
- TCRX 509.4K
- Earning Date
- JHS 01-01-0001
- TCRX 11-11-2025
- Dividend Yield
- JHS 3.96%
- TCRX N/A
- EPS Growth
- JHS N/A
- TCRX N/A
- EPS
- JHS 0.02
- TCRX N/A
- Revenue
- JHS N/A
- TCRX $6,961,000.00
- Revenue This Year
- JHS N/A
- TCRX $255.18
- Revenue Next Year
- JHS N/A
- TCRX N/A
- P/E Ratio
- JHS $553.50
- TCRX N/A
- Revenue Growth
- JHS N/A
- TCRX N/A
- 52 Week Low
- JHS $9.76
- TCRX $1.02
- 52 Week High
- JHS $11.25
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- JHS 65.87
- TCRX 62.41
- Support Level
- JHS $11.70
- TCRX $1.90
- Resistance Level
- JHS $12.09
- TCRX $2.40
- Average True Range (ATR)
- JHS 0.13
- TCRX 0.18
- MACD
- JHS 0.01
- TCRX 0.02
- Stochastic Oscillator
- JHS 68.37
- TCRX 67.14
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.